Arca Biopharma Inc (ABIO)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
CEO:
Michael R. Bristow
Employees:
6
11080 CIRCLEPOINT ROAD, SUITE 140, WESTMINSTER, CO 80020
720-940-2200

ARCA biopharma, Inc. develops and commercializes genetically targeted therapies for cardiovascular diseases. The company was incorporated in 2004 and is headquartered in Westminster, Colorado. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 and Gencaro.

Data derived from most recent annual or quarterly report
Market Cap 30.261 Million Shares Outstanding14.41 Million Avg 30-day Volume 25.683 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.55
Price to Revenue0.0 Debt to Equity0.0 EBITDA-9.003 Million
Price to Book Value0.7075 Operating Margin0.0 Enterprise Value-12.174 Million
Current Ratio32.94 EPS Growth0.57 Quick Ratio32.267
1 Yr BETA 0.1851 52-week High/Low 2.7 / 1.85 Profit Margin0.0
Operating Cash Flow Growth53.9725 Altman Z-Score5.5489 Free Cash Flow to Firm -7.183 Million
View SEC Filings from ABIO instead.

View recent insider trading info

Arca Biopharma Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ABIO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ABIO

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-12-19 by MA-WEAVER JACOB
  • 4: filed on 2022-12-19 by WOOSLEY RAYMOND L.
  • 4: filed on 2022-12-19 by MITCHELL DANIEL J
  • 4: filed on 2022-12-19 by Grais Linda
  • 4: filed on 2022-12-19 by HOVE ANDERS D
  • 4: filed on 2022-12-19 by CONWAY ROBERT E
  • 4: filed on 2022-12-19 by Flynn James P
  • 3: filed on 2022-12-19 by Flynn James P
  • 4: filed on 2022-12-09 by KEUER THOMAS A
  • 4: filed on 2022-12-09 by DEKKER C. JEFFREY

    • Events (8k)

  • 8-K: filed on 2023-04-24:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-24:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-19:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-09:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-20:
    Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-21:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MITCHELL DANIEL J

    • Director
    		 6,611 2022-12-15 1

    CONWAY ROBERT E

    • Director
    • CHAIRMAN OF THE BOARD
    		 56,000 2022-12-15 1

    HOVE ANDERS D

    • Director
    		 6,000 2022-12-15 1

    GRAIS LINDA

    • Director
    		 6,000 2022-12-15 1

    WOOSLEY RAYMOND L.

    • Director
    		 6,000 2022-12-15 1

    FUNICULAR FUNDS, LP

    MA-WEAVER JACOB

    • Director
    • 10% Owner
    • SEE FOOTNOTE 1SEE FOOTNOTE 1
    		 4,048,452 2022-12-15 3

    FLYNN JAMES P

    • Director
    		 12,000 2022-12-15 2

    KEUER THOMAS A CHIEF OPERATING OFFICER

    • Officer
    		 40,730 2022-12-08 1

    DEKKER C. JEFFREY CHIEF FINANCIAL OFFICER

    • Officer
    		 40,000 2022-12-08 1

    FUNICULAR FUNDS, LP

    • 10% Owner
    • SEE FOOTNOTE 1
    		 2,580,452 2022-07-01 2

    MA-WEAVER JACOB

    • Director
    • 10% Owner
    • SEE FOOTNOTE 1
    		 2,580,452 2022-06-15 3

    FUNICULAR FUND, LP

    MA-WEAVER JACOB

    • SEE FOOTNOTE 1SEE FOOTNOTE 1
    		 2,594,952 2022-05-23 0

    FUNICULAR FUND, LP

    • SEE FOOTNOTE 1
    		 1,822,651 2022-04-01 0

    BRISTOW MICHAEL R PRES. & CHIEF EXECUTIVE OFFIC

    • Officer
    • Director
    		 99,808 2021-12-14 0

    OZEROFF CHRISTOPHER DAVID S.V.P., GENERAL COUNSEL

    • Officer
    		 78,470 2021-12-14 0

    SELBY BRIAN L. VP, FINANCE

    • Officer
    		 0 2020-12-21 0

    BARRIS PETER J

    • 10% Owner
    		 No longer subject to file 2018-02-26 0

    MOTT DAVID M

    • 10% Owner
    		 No longer subject to file 2018-02-26 0

    MAKOWER JOSHUA

    • 10% Owner
    		 No longer subject to file 2018-02-26 0

    SANDELL SCOTT D

    • 10% Owner
    		 No longer subject to file 2018-02-26 0

    BASKETT FOREST

    • 10% Owner
    		 No longer subject to file 2018-02-26 0

    VENROCK HEALTHCARE CAPITAL PARTNERS LP

    VHCP CO-INVESTMENT HOLDINGS, LLC

    VHCP MANAGEMENT, LLC

    VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P.

    VHCP CO-INVESTMENT HOLDINGS II, LLC

    VHCP MANAGEMENT II, LLC

    KOH BONG Y

    SHAH NIMISH P

    • 10% Owner
    		 No longer subject to file 2018-02-26 0

    VISWANATHAN RAVI

    • 10% Owner
    		 No longer subject to file 2018-02-26 0

    SONSINI PETER W.

    • 10% Owner
    		 No longer subject to file 2018-02-26 0

    FLORENCE ANTHONY A. JR.

    • 10% Owner
    		 No longer subject to file 2018-02-26 0

    SAKODA JON

    • 10% Owner
    		 No longer subject to file 2018-02-26 0

    GROWTH EQUITY OPPORTUNITIES IV, LLC

    NEW ENTERPRISE ASSOCIATES 15, L.P.

    NEA PARTNERS 15, L.P.

    NEA 15 GP, LLC

    • 10% Owner
    		 No longer subject to file 2018-02-26 0

    KOLLURI KRISHNA KITTU

    • 10% Owner
    		 10,221,465 2015-06-16 0

    WELLER HARRY R

    • 10% Owner
    		 10,221,465 2015-06-16 0

    VENROCK HEALTHCARE CAPITAL PARTNERS LP

    VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P.

    VHCP CO-INVESTMENT HOLDINGS, LLC

    VHCP CO-INVESTMENT HOLDINGS II, LLC

    KOH BONG Y

    HOVE ANDERS D

    VHCP MANAGEMENT, LLC

    VHCP MANAGEMENT II, LLC

    • 10% Owner
    		 10,789,324 2015-06-16 0

    MCCORMACK RILEY

    • 10% Owner
    		 No longer subject to file 2015-01-14 0

    WHEELER PATRICK M CHIEF FINANCIAL OFFICER

    • Officer
    		 101,510 2014-09-18 0

    ZABRISKIE JOHN L

    • Director
    		 0 2013-09-17 0

    ATLAS VENTURE FUND VII L P

    ATLAS VENTURE ASSOCIATES VII, L.P.

    • 10% Owner
    		 1,579,542 2012-10-25 0

    FORMELA JEAN FRANCOIS

    • Director
    • 10% Owner
    		 1,579,542 2012-10-22 0

    BREWER RICHARD B

    • Director
    		 0 2012-02-10 0

    SOBEL BURTON E

    • Director
    		 0 2012-02-10 0

    ATLAS VENTURE FUND VII L P

    • 10% Owner
    		 1,337,612 2010-03-29 0

    LOVE TED W

    • Director
    		 0 2010-02-05 0

    PENDERGAST MARY K

    • Director
    		 0 2010-02-05 0

    FREYTAG J WILLIAM

    • Director
    		 0 2010-02-05 0

    LOWE DAVID GEORGE

    • Director
    		 No longer subject to file 2009-07-17 0

    FALBERG KATHRYN E CFO AND COO

    • Officer
    		 0 2009-06-25 0

    SKYLINE VENTURE PARTNERS QUALIFIED PURCHASER FUND IV L P

    • FORMER 10% OWNER
    		 No longer subject to file 2009-06-11 0

    BOULDER VENTURES IV ANNEX LP

    BOULDER VENTURES IV LP

    BV PARTNERS IV, L.L.C.

    FIDLER JOSH E

    JONES ANDREW E

    LEFKOFF KYLE

    MACKS LAWRENCE M

    ROSHKO PETER

    • 10% Owner
    		 No longer subject to file 2009-04-06 0

    ST LAURENT RANDALL EVP COMMERCIAL OPERATIONS

    • Officer
    		 0 2009-01-27 0

    BENDEKGEY E LEE CFO AND TREASURER

    • Officer
    		 1,502 2008-12-31 0

    PERRY MARK L

    • Director
    		 0 2008-06-04 0

    GAVIN JAMES R III

    • Director
    		 0 2008-06-04 0

    POPOVITS KIMBERLY J

    • Director
    		 0 2008-06-04 0

    ZUBROW BARRY L

    • Director
    		 20,000 2007-05-31 0

    TITUS GARY CHIEF ACCT.OFFICER

    • Officer
    		 2,633 2006-08-30 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ARCA BIOPHARMA INC ABIO 2023-06-02 22:15:04 UTC 3.5573 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 21:45:04 UTC 3.5573 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 21:15:04 UTC 3.5573 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 20:45:03 UTC 3.5573 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 20:15:05 UTC 3.5573 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 19:45:04 UTC 3.5573 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 19:15:04 UTC 3.5573 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 18:45:04 UTC 3.5573 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 18:15:04 UTC 3.5573 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 17:45:03 UTC 3.5573 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 17:15:04 UTC 3.5573 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 16:45:03 UTC 3.5673 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 16:15:04 UTC 3.5673 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 15:45:04 UTC 3.5673 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 15:15:03 UTC 3.5673 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 14:45:04 UTC 3.5673 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 14:15:03 UTC 3.5673 1.5027 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 13:45:03 UTC 3.5657 1.5043 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 13:15:04 UTC 3.5657 1.5043 750000
    ARCA BIOPHARMA INC ABIO 2023-06-02 12:45:03 UTC 3.5657 1.5043 750000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments